Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03480971 · ClinicalTrials.gov registry record · Phase 2
Treatment of Radiation and Cisplatin Induced Toxicities with Tempol
A Phase 2 study of Mucositis and Ototoxicity, sponsored by Matrix Biomed.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 9
- Study locations
NCT03480971 is a Phase 2 study of Mucositis and Ototoxicity that is actively recruiting participants, run by Matrix Biomed. The registered enrollment target is 120 participants, above the 31-participant average among 4 other Mucositis trials with a reported enrollment target (287% higher). The trial reports 9 study locations across 4 states.
The verdict
NCT03480971, a Phase 2 study of Mucositis and Ototoxicity, is actively recruiting participants, sponsored by Matrix Biomed.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 9
- Study locations
Study Summary
A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients. Over the course of the 10 week trial, mucositis, nephrotoxicity, and ototoxicity will be monitored and assessed.
Conditions Studied
Interventions
- DRUG Tempol
- DRUG Placebo Solution
Study Locations (9)
California
- UCSD - La Jolla
- Mercy Medical Center - Merced
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
- Central Coast Medical Oncology - Santa Maria
- Mission Hope Health Center - Santa Maria
Washington
- Seattle Cancer Care Alliance - Seattle
- University of Washington Medical Center - Seattle
New York
- Montefiore Medical Center-Einstein Campus - The Bronx
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2019-05-13 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03480971
The ClinicalTrials.gov registry entry for NCT03480971 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 31-participant average among 4 other Mucositis trials with a reported enrollment target (287% higher). The listed sponsor is Matrix Biomed, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Mucositis appearing as the primary indexed condition, and to 2 interventions - of which Tempol is the first listed.
NCT03480971 reports 9 study locations spanning 4 distinct geographic areas - top geographies include California, Washington, New York.
Frequently Asked Questions
What is clinical trial NCT03480971 about?
NCT03480971 is a clinical study titled "Treatment of Radiation and Cisplatin Induced Toxicities with Tempol". A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients. Over the course of the 10 week trial, mucositis, nephrotoxicity, and ototoxicity will be monitored and assessed.
What is the current status of trial NCT03480971?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2019-05-13. Estimated completion is 2025-12.
What conditions does trial NCT03480971 study?
This clinical trial studies the following conditions: Mucositis, Ototoxicity, Nephrotoxicity.
What interventions are being tested in trial NCT03480971?
The interventions under investigation include: Tempol (DRUG), Placebo Solution (DRUG).
Who is sponsoring clinical trial NCT03480971?
This trial is sponsored by Matrix Biomed, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03480971 being conducted?
This trial has 9 study locations across California, New York, North Carolina, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mucositis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effect Of Enamel Matrix Derivatives On Gingival Tissue Thickness
RECRUITING · NA
-
Sensory Evaluation of Oral Nutrition Supplements in Patients at Risk for Mucositis Undergoing Cancer Treatment
COMPLETED · NA
-
Low-Level Laser Therapy for Prevention of Oral Mucositis
COMPLETED · NA
-
Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.